<DOC>
	<DOCNO>NCT02968719</DOCNO>
	<brief_summary>A Phase 1 , Randomized , Open-Label , 3-Way Crossover , Pilot , Pharmacokinetic Study Evaluate Steady State Pharmacokinetics Once-Weekly Application Corplex Donepezil Transdermal Delivery System ( TDS ) Compared Daily Oral Administration Aricept Healthy Adult Subjects</brief_summary>
	<brief_title>A Phase 1 , Corplex™ Donepezil Trans-dermal System Compared Oral Aricept®</brief_title>
	<detailed_description>60 male female subject enrol Subjects receive 2 version once-weekly Corplex Donepezil TDS QD oral Aricept ; administer 35 day 3 different treatment period . For treatment period ; Subjects receive lead-in dose approximately 5 mg donepezil/day 7 day commence dose 10 mg donepezil/day 28 day . Blood sample donepezil PK red blood cell ( RBC ) AChEI ( potential pharmacodynamic [ PD ] marker ) collect pre-dose Week 8 . Adhesion skin irritation monitor throughout TDS Treatments . A washout period least 21 day last study drug administration ( oral administration removal TDS , appropriate ) treatment period first application TDS oral drug administration , appropriate , follow treatment period . Safety monitor throughout study adverse event reporting , repeat clinical laboratory evaluation</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Donepezil</mesh_term>
	<criteria>Healthy , adult , Caucasian , male female ≥18 year age , screen Body mass index ≥ 18.0 ≤ 32.0 kg/m2 screen Medically healthy clinically significant medical history , physical examination , laboratory profile , vital sign electrocardiogram ( ECGs ) , deem Investigator . Have Fitzpatrick skin type I , II III skin colorimeter score equivalent allow Fitzpatrick skin type . Key History presence hypersensitivity idiosyncratic reaction study drug relate compound ( include piperidine derivative cholinesterase inhibitor ) Has intolerance venipuncture and/or inability comply extensive blood sampling require study suitable vein arm Potential occupational exposure anticholinesterase agent . Female subject positive pregnancy test lactate Positive urine drug alcohol result Estimated creatinine clearance nonelderly subject &lt; 80 mL/min screen elderly subject ( i.e. , ≥55 year age ) &lt; 60 mL/min screen Hemoglobin value le 11.5 g/dl female , 13.0 g/dl male screen first checkin Any follow drug 28 day prior first dose study drug Treatment Period 1 throughout study : significant inducer cytochrome P450 ( CYP ) enzymes and/or Pglycoprotein antiinflammatory drug cyclooxygenase 2 ( COX2 ) analgesic betablockers ; antifungal medication ; antihistamine ; cholinergics anticholinergic ; oral corticosteroid ; Prolia ; Adjuvant analgesic Muscle relaxant , antiParkinsonian neuroleptic medication prior first dose study drug History presence excessive hairy skin application sit deem Investigator potentially interfere drug absorption History presence significant skin damage , diffuse skin disease , scar , tattoos application site skin disturbance deem Investigator potentially interfere drug absorption irritation assessment Use donepezil hydrochloride relate drug within 60 day prior first study drug administration Participation another clinical study within 60 day prior first study drug administration Clinically significant depression symptom suicidal ideation behavior determine investigator :</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>